BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 25723087)

  • 1. Will nanobiosensors change therapeutic drug monitoring? The case of methotrexate.
    Masson JF; Pelletier JN
    Nanomedicine (Lond); 2015 Mar; 10(4):521-4. PubMed ID: 25723087
    [No Abstract]   [Full Text] [Related]  

  • 2. Miniature multi-channel SPR instrument for methotrexate monitoring in clinical samples.
    Zhao SS; Bukar N; Toulouse JL; Pelechacz D; Robitaille R; Pelletier JN; Masson JF
    Biosens Bioelectron; 2015 Feb; 64():664-70. PubMed ID: 25441416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring methotrexate in clinical samples from cancer patients during chemotherapy with a LSPR-based competitive sensor.
    Zhao SS; Bichelberger MA; Colin DY; Robitaille R; Pelletier JN; Masson JF
    Analyst; 2012 Oct; 137(20):4742-50. PubMed ID: 22943049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Methotrexate].
    Yamada M
    Nihon Rinsho; 1999 Sep; 57 Suppl():421-4. PubMed ID: 10543143
    [No Abstract]   [Full Text] [Related]  

  • 5. [Methotrexate (MTX)].
    Yamada M
    Nihon Rinsho; 1995 Feb; 53 Su Pt 1():1053-5. PubMed ID: 8753620
    [No Abstract]   [Full Text] [Related]  

  • 6. Naked-eye nanobiosensor for therapeutic drug monitoring of methotrexate.
    Yockell-Lelièvre H; Bukar N; Toulouse JL; Pelletier JN; Masson JF
    Analyst; 2016 Jan; 141(2):697-703. PubMed ID: 26229988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring of methotrexate on the pediatric oncology ward: can blood sampling from central venous accesses substitute for capillary finger punctures?
    Ritzmo C; Albertioni F; Cosic K; Söderhäll S; Eksborg S
    Ther Drug Monit; 2007 Aug; 29(4):447-51. PubMed ID: 17667799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of 7-OH methotrexate metabolite on clinical relevance of methotrexate determination.
    Klapkova E; Kukacka J; Kotaska K; Suchanska I; Urinovska R; Prusa R
    Clin Lab; 2011; 57(7-8):599-606. PubMed ID: 21888024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter method evaluation of the ARK™ Methotrexate Immunoassay.
    Godefroid MJ; von Meyer A; Parsch H; Streichert T; Verstraete AG; Stove V
    Clin Chem Lab Med; 2014 Feb; 52(2):e13-6. PubMed ID: 24114913
    [No Abstract]   [Full Text] [Related]  

  • 10. High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy.
    Min Y; Qiang F; Peng L; Zhu Z
    Biopharm Drug Dispos; 2009 Nov; 30(8):437-47. PubMed ID: 19746402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A U-HPLC-ESI-MS/MS-based stable isotope dilution method for the detection and quantitation of methotrexate in plasma.
    den Boer E; Heil SG; van Zelst BD; Meesters RJ; Koch BC; Te Winkel ML; van den Heuvel-Eibrink MM; Luider TM; de Jonge R
    Ther Drug Monit; 2012 Aug; 34(4):432-9. PubMed ID: 22689188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic drug monitoring of methotrexate after its administration in high-dose protocols].
    Le Guellec C; Blasco H; Benz I; Hulin A;
    Therapie; 2010; 65(3):163-9. PubMed ID: 20699066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma.
    Johansson ÅM; Hill N; Perisoglou M; Whelan J; Karlsson MO; Standing JF
    Ther Drug Monit; 2011 Dec; 33(6):711-8. PubMed ID: 22105588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surface plasmon resonance in monitoring of complement activation on biomaterials.
    Arima Y; Toda M; Iwata H
    Adv Drug Deliv Rev; 2011 Sep; 63(12):988-99. PubMed ID: 21803085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unexpected overestimation of methotrexate plasma concentrations: analysis of a single center pediatric population.
    Guerriero E; Simon N; Nelken B; Baldeyrou B; Djobo B; Vasseur M; Allorge D; Décaudin B; Odou P
    Ther Drug Monit; 2014 Aug; 36(4):499-504. PubMed ID: 25014075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpected overestimation of methotrexate plasma concentrations: importance of the assay implementation and its validation.
    Godefroid M; Verstraete AG; Stove V
    Ther Drug Monit; 2015 Jun; 37(3):417-8. PubMed ID: 25384120
    [No Abstract]   [Full Text] [Related]  

  • 18. Reduced elimination of Methotrexate in an adult with trisomy 21 and acute lymphoblastic leukaemia.
    Thachil J
    Leuk Res; 2007 Oct; 31(10):1452-3. PubMed ID: 17178159
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of time to clearance of high-dose methotrexate using the ARK immunoassay in pediatric hematology/oncology patients: A single-center experience.
    Kowalski KE; Higgins TA
    Pediatr Blood Cancer; 2021 Mar; 68(3):e28788. PubMed ID: 33164288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate.
    Held-Warmkessel J
    Clin J Oncol Nurs; 2000; 4(4):187-8. PubMed ID: 11261104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.